AmorphOX-Semaglutide

About Orexo

Orexo is a publicly traded, commercial-stage Swedish pharmaceutical company with a foundation in proprietary drug delivery technology. Its core platform, AmorphOX®, is a powder-based technology designed to enhance the bioavailability and stability of both small and large molecules, enabling novel administration routes. The company has a diversified pipeline focused on rescue medications and treatments for substance use disorders, leveraging both internal development and strategic partnerships. Orexo generates revenue from its commercial product, Zubsolv®, while advancing key late-stage programs like OX640 and Izipry.

Therapeutic Areas